Latest & greatest articles for gabapentin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on gabapentin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on gabapentin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for gabapentin

41. Limited evidence does not support use of gabapentin as stand-alone therapy for acute postoperative pain

Limited evidence does not support use of gabapentin as stand-alone therapy for acute postoperative pain Limited evidence does not support use of gabapentin as stand-alone therapy for acute postoperative pain ADA Websites Access news, member benefits and ADA policy Attend ADA's premier event Access cutting-edge continuing education courses Find evidence to support your clinical decisions Access member-only practice content Investing in better oral health for all. Together. Take advantage (...) evidence does not support use of gabapentin as stand-alone therapy for acute postoperative pain Arthur Jeske DMD, PhD; James Zahrowski DMD, MS, PharmD . Overview Systematic Review Conclusion Gabapentin (250 mg) is statistically superior to placebo for treating established acute postoperative pain. However, to achieve at least 50 percent pain relief over six hours, the number of patients needed to treat was 11, which suggests gabapentin has limited clinical value and is inferior to common analgesics

2011 ADA Center for Evidence-Based Dentistry

42. WITHDRAWN: Gabapentin for acute and chronic pain. (PubMed)

WITHDRAWN: Gabapentin for acute and chronic pain. February 2009: The authors are aware of unpublished trial data for Gabapentin which could affect the results of this review. This information together with that from trials published since 2005, will be considered when this review is updated in 2009.Anticonvulsant drugs have been used in the management of pain since the 1960s. The clinical impression is that they are useful for chronic neuropathic pain, especially when the pain is lancinating (...) or burning.To evaluate the analgesic effectiveness and adverse effects of gabapentin for pain management in clinical practice.Randomised trials of gabapentin in acute, chronic or cancer pain were identified by MEDLINE (1966 to Nov 2004), EMBASE (1994 to Nov 2004), SIGLE (1980 to Jan 2004) and the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library, Issue 4, 2004). Additional studies were identified from the reference list of the retrieved papers, and by contacting investigators

2011 Cochrane

43. Horizant (gabapentin enacarbil) Extended-Release Tablets

Horizant (gabapentin enacarbil) Extended-Release Tablets Drug Approval Package: Horizant (gabapentin enacarbil) NDA #022399 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Horizant (gabapentin enacarbil) Extended-Release Tablets Company: GlaxoSmithKline Application No.: 022399 Approval Date: 4/06/2011 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

2011 FDA - Drug Approval Package

44. Cochrane systematic review: Clonidine, SSRIs, SNRIs and gabapentin reduce hot flushes in women with a history of breast cancer; relaxation therapy may have a mild effect in the short term

Cochrane systematic review: Clonidine, SSRIs, SNRIs and gabapentin reduce hot flushes in women with a history of breast cancer; relaxation therapy may have a mild effect in the short term Clonidine, SSRIs, SNRIs and gabapentin reduce hot flushes in women with a history of breast cancer; relaxation therapy may have a mild effect in the short term | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings (...) via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Clonidine, SSRIs, SNRIs and gabapentin

2011 Evidence-Based Nursing

45. Pregabalin and gabapentin in matched patients with peripheral neuropathic pain in routine medical practice in a primary care setting: findings from a cost-consequences analysis in a nested case-control study

Pregabalin and gabapentin in matched patients with peripheral neuropathic pain in routine medical practice in a primary care setting: findings from a cost-consequences analysis in a nested case-control study Pregabalin and gabapentin in matched patients with peripheral neuropathic pain in routine medical practice in a primary care setting: findings from a cost-consequences analysis in a nested case-control study Pregabalin and gabapentin in matched patients with peripheral neuropathic pain (...) was to assess the costs and benefits of pregabalin and gabapentin, for the treatment of adults with peripheral neuropathic pain, in routine medical practice. The authors concluded that pregabalin seemed to reduce the mean weekly intensity of pain more than gabapentin, with no significant difference in costs. The reporting and methods were satisfactory. The authors' conclusion appears to be appropriate, but highly uncertain. Type of economic evaluation Cost-effectiveness analysis, cost-utility analysis Study

2010 NHS Economic Evaluation Database.

46. Gabapentin tablets versus capsules: a review of the evidence regarding appropriate use

Gabapentin tablets versus capsules: a review of the evidence regarding appropriate use Gabapentin tablets versus capsules: a review of the evidence regarding appropriate use Gabapentin tablets versus capsules: a review of the evidence regarding appropriate use Canadian Agency for Drugs and Technologies in Health Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made (...) for the HTA database. Citation Canadian Agency for Drugs and Technologies in Health. Gabapentin tablets versus capsules: a review of the evidence regarding appropriate use. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2010 Authors' conclusions There is a paucity of primary studies comparing the potential for misuse of gabapentin capsules and tablets. There is evidence from case reports that gabapentin capsules may be subject to misuse in certain populations, particularly those

2010 Health Technology Assessment (HTA) Database.

47. New users of the anticonvulsants gabapentin, lamotrigine, oxcarbazepine or tiagabine are at increased risk of suicidal acts compared with new users of topiramate

New users of the anticonvulsants gabapentin, lamotrigine, oxcarbazepine or tiagabine are at increased risk of suicidal acts compared with new users of topiramate New users of the anticonvulsants gabapentin, lamotrigine, oxcarbazepine or tiagabine are at increased risk of suicidal acts compared with new users of topiramate | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser (...) at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here New users of the anticonvulsants gabapentin, lamotrigine

2010 Evidence-Based Mental Health

48. Gabapentin and pregabalin in the treatment of fibromyalgia: a systematic review and a meta-analysis

Gabapentin and pregabalin in the treatment of fibromyalgia: a systematic review and a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

49. Gabapentin versus tricyclic antidepressants for diabetic neuropathy and post-herpetic neuralgia: discrepancies between direct and indirect meta-analyses of randomized controlled trials (PubMed)

Gabapentin versus tricyclic antidepressants for diabetic neuropathy and post-herpetic neuralgia: discrepancies between direct and indirect meta-analyses of randomized controlled trials Previous systematic reviews concluded that tricyclics antidepressants are superior to gabapentin for neuropathic pain, but were based on indirect comparisons from placebo-controlled trials.To evaluate gabapentin versus tricyclic antidepressants for diabetic neuropathy and post-herpetic neuralgia, using direct (...) and indirect comparisons.MEDLINE (1966 to March Week 4 2008), the Cochrane central register of controlled trials (1st quarter 2008), and reference lists.We selected randomized trials directly comparing gabapentin versus tricyclic antidepressants or comparing either of these medications versus placebo.Studies were reviewed, abstracted, and quality-rated by two independent investigators using predefined criteria.We performed a meta-analysis of head-to-head trials using a random effects model and compared

Full Text available with Trip Pro

2009 EvidenceUpdates

50. Gabapentin for pain: New evidence from hidden data

Gabapentin for pain: New evidence from hidden data [75] Gabapentin for pain: New evidence from hidden data | Therapeutics Initiative Independent Healthcare Evidence > > [75] Gabapentin for pain: New evidence from hidden data Background Gabapentin (Neurontin) was licensed in Canada in 1993 for adjunctive treatment of epilepsy. In 1998 two double blind randomized controlled trials (DBRCT) suggested mild analgesic effects of gabapentin in painful diabetic peripheral neuropathy (PDPN) and post (...) -herpetic neuralgia (PHN) . Subsequently, unapproved use of gabapentin exploded for pain, migraine, and even as a “mood stabilizer”. (Jan-Feb 2000) reviewed gabapentin for pain. It noted that gabapentin is eliminated by kidney filtration (half-life 6 hours with normal renal function) and that it reduced pain by a mean of 1-2 points on a pain score of 0-10, over 2 weeks, NNT=4 for “moderate or marked” benefit. The Letter concluded: “Gabapentin benefits at best a minority of patients with painful diabetic

2009 Therapeutics Letter

51. Gabapentin versus tricyclic antidepressants for diabetic neuropathy and post-herpetic neuralgia: discrepancies between direct and indirect meta-analyses of randomized controlled trials

Gabapentin versus tricyclic antidepressants for diabetic neuropathy and post-herpetic neuralgia: discrepancies between direct and indirect meta-analyses of randomized controlled trials Gabapentin versus tricyclic antidepressants for diabetic neuropathy and post-herpetic neuralgia: discrepancies between direct and indirect meta-analyses of randomized controlled trials Gabapentin versus tricyclic antidepressants for diabetic neuropathy and post-herpetic neuralgia: discrepancies between direct (...) and indirect meta-analyses of randomized controlled trials Chou R, Carson S, Chan B K CRD summary This review concluded that there was no difference in pain relief between gabapentin and tricyclic antidepressants in patients with diabetic neuropathy or post-herpetic neuralgia, although direct evidence was limited. The review was well conducted and these findings are likely to be reliable. Authors' objectives To compare gabapentin with tricyclic antidepressants for the treatment of diabetic neuropathy

2009 DARE.

52. Treatment of fibromyalgia syndrome with gabapentin and pregabalin: a meta-analysis of randomized controlled trials

Treatment of fibromyalgia syndrome with gabapentin and pregabalin: a meta-analysis of randomized controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

53. Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain

Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

54. Gabapentin for the treatment of hot flashes in women with natural or tamoxifen-induced menopause: a systematic review and meta-analysis

Gabapentin for the treatment of hot flashes in women with natural or tamoxifen-induced menopause: a systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

55. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial. (PubMed)

Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial. Drugs for neuropathic pain have incomplete efficacy and dose-limiting side-effects when given as monotherapy. We assessed the efficacy and tolerability of combined nortriptyline and gabapentin compared with each drug given alone.In this double-blind, double-dummy, crossover trial, patients with diabetic polyneuropathy or postherpetic neuralgia, and who had a daily (...) pain score of at least 4 (scale 0-10), were enrolled and treated at one study site in Canada between Nov 5, 2004, and Dec 13, 2007. 56 patients were randomised in a 1:1:1 ratio with a balanced Latin square design to receive one of three sequences of daily oral gabapentin, nortriptyline, and their combination. In sequence, a different drug was given to each randomised group in three treatment periods. During each 6-week treatment period, drug doses were titrated towards maximum tolerated dose

2009 Lancet Controlled trial quality: predicted high

56. Gabapentin does not reduce post-thoracotomy shoulder pain: a randomized, double-blind placebo-controlled study (PubMed)

Gabapentin does not reduce post-thoracotomy shoulder pain: a randomized, double-blind placebo-controlled study Despite adequate epidural analgesia, up to 97% of patients undergoing thoracotomy experience ipsilateral shoulder pain. In this setting, this study evaluated the safety and the efficacy of pre-emptive gabapentin.A double-blind, placebo-controlled study was undertaken in 51 patients randomized into two groups. Two hours before surgery, 23 patients received gabapentin 1200 mg po (Group G (...) in Group P had sedation scores > 1, compared to 0/28 patients in Group G (P = 0.05).Pre-emptively administered gabapentin, 1200 mg, does not reduce the incidence, or the severity, of post-thoracotomy shoulder pain in patients receiving thoracic epidural analgesia.

Full Text available with Trip Pro

2008 EvidenceUpdates Controlled trial quality: uncertain

57. Cost-effectiveness analysis of a lidocaine 5% medicated plaster compared with gabapentin and pregabalin for treating postherpetic neuralgia: a German perspective

Cost-effectiveness analysis of a lidocaine 5% medicated plaster compared with gabapentin and pregabalin for treating postherpetic neuralgia: a German perspective Cost-effectiveness analysis of a lidocaine 5% medicated plaster compared with gabapentin and pregabalin for treating postherpetic neuralgia: a German perspective Cost-effectiveness analysis of a lidocaine 5% medicated plaster compared with gabapentin and pregabalin for treating postherpetic neuralgia: a German perspective Liedgens H (...) , Hertel N, Gabriel A, Nuijten M, Dakin H, Mitchell S, Poulsen Nautrup B Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to examine the cost-effectiveness of the lidocaine 5% medicated plaster versus gabapentin

2008 NHS Economic Evaluation Database.

58. Use of gabapentin for perioperative pain control: a meta-analysis

Use of gabapentin for perioperative pain control: a meta-analysis Use of gabapentin for perioperative pain control: a meta-analysis Use of gabapentin for perioperative pain control: a meta-analysis Peng P W, Wijeysundera D N, Li C C CRD summary This generally well-conducted review assessed the use of gabapentin for peri-operative pain control in adults. The authors concluded that gabapentin is associated with a reduction in pain, analgesic consumption and opioid-related side-effects (...) , but there is an increased risk of dizziness and sedation. These conclusions appear to be supported by the data presented, although there may be some risk of publication bias. Authors' objectives To assess the analgesic effectiveness, opioid-sparing effects and side-effects of gabapentin used peri-operatively. Searching MEDLINE (1966 to February 2006), EMBASE (1980 to February 2006), the Cochrane Controlled Trials Register (Issue 1, 2006), Science Citation Index, Current Controlled Trials Register, TextMed, Science

2007 DARE.

59. Cost-effectiveness of a lidocaine 5% medicated plaster relative to gabapentin for postherpetic neuralgia in the United Kingdom

Cost-effectiveness of a lidocaine 5% medicated plaster relative to gabapentin for postherpetic neuralgia in the United Kingdom Cost-effectiveness of a lidocaine 5% medicated plaster relative to gabapentin for postherpetic neuralgia in the United Kingdom Cost-effectiveness of a lidocaine 5% medicated plaster relative to gabapentin for postherpetic neuralgia in the United Kingdom Dakin H, Nuijten M, Liedgens H, Poulsen Nautrup B Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to assess the cost-effectiveness of lidocaine 5% medicated plasters in place of gabapentin in the treatment of postherpetic neuralgia, in patients who had insufficient pain relief with standard analgesics and who could not tolerate, or had

2007 NHS Economic Evaluation Database.

60. Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia

Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 NHS Economic Evaluation Database.